PYC Therapeutics has made significant progress across its four RNA therapeutic programs, including dose escalation approvals in its Polycystic Kidney Disease trial and orphan drug designation for its Retinitis Pigmentosa candidate, supported by a robust cash position of $669 million.
- Phase 1b dose escalation approved in PKD program
- Orphan Drug Designation granted for RP11 candidate
- Sustained visual improvements reported in ADOA trials
- Phelan-McDermid Syndrome program advancing preclinical studies
- $669 million cash on hand as of June 2026
Dose Escalation and Extended Dosing in Polycystic Kidney Disease Trial
PYC Therapeutics (ASX:PYC) has secured Safety Review Committee (SRC) approval to escalate dosing in its ongoing Phase 1b Multiple Ascending Dose (MAD) study for Polycystic Kidney Disease (PKD), moving into a higher dose cohort of 2.4 mg/kg. This follows earlier safety clearances from the SRC after initial dosing in Part B of the Single Ascending Dose (SAD) study. Additionally, the SRC approved an Open-Label Extension (OLE) allowing continuous dosing for up to 24 months, aligning with the planned registrational Phase 2/3 trial timeline.
The PKD program targets a disease affecting over 10 million people worldwide, many of whom lack effective treatment options. PYC’s RNA therapeutic candidate aims to address the underlying genetic causes. The company expects to present Phase 1a SAD data in the second half of 2026 and Phase 1b MAD results in 2027, which will be critical to establishing clinical proof of concept and advancing to registrational studies.
Progress in Ophthalmology Programs with Clinical and Preclinical Data
In its Autosomal Dominant Optic Atrophy (ADOA) program, PYC has enrolled patients across multiple dose cohorts in the Phase 1/2 MAD study. Notably, recent data from Non-Human Primates demonstrated sustained target gene expression in the retina four months after a single dose, while patients in ongoing trials showed sustained improvements in visual acuity and reduced retinal stress. These findings bolster the safety and efficacy profile of PYC-001 and support ongoing efforts to establish clinical proof of concept.
Similarly, the Retinitis Pigmentosa type 11 (RP11) program received Orphan Drug Designation from the European Medicines Agency, a regulatory milestone that could facilitate expedited development and market access. Phase 2 trials are underway, with an update on vision improvements expected in Q4 2026. The company is preparing for a potential registrational Phase 3 trial pending these outcomes.
Advancement of Phelan-McDermid Syndrome Program and Preclinical Milestones
PYC’s Phelan-McDermid Syndrome (PMS) program, targeting a severe neurodevelopmental disorder affecting approximately 1 in 7,300 individuals, has completed dose-range finding studies in rodents and Non-Human Primates and commenced Good Laboratory Practice toxicology assessments. Recent presentations at the PMS Foundation Family Conference highlighted promising data from patient-derived models, showing restoration of neuronal communication deficits and maintenance of natural protein isoform balance following treatment with PYC-002. The company aims to initiate first-in-human trials in 2027, contingent on regulatory alignment.
Robust Financial Position and Corporate Developments
As of 30 June 2026, PYC Therapeutics reported a strong cash position of $669 million, providing a substantial runway to support ongoing clinical trials and research activities. Operating cash flow remained positive in the quarter, bolstered by government grants and interest income. Related party payments, including executive and non-executive director fees, totalled $645,000 for the quarter.
The company also strengthened its leadership team with key appointments: Thomas Ulmer as Chief Financial Officer, Jonathan Riley as General Counsel and Co-Company Secretary, and Steve Ledger as Co-Company Secretary. An Extraordinary General Meeting held on 15 July approved resolutions related to a Long-Term Incentive Plan and director remuneration caps, reflecting ongoing corporate governance enhancements.
Bottom Line?
PYC’s clinical progress across multiple RNA therapeutic programs, coupled with a solid cash reserve, positions it well for critical data readouts and regulatory milestones in the coming 18 months.
Questions in the middle?
- Will Phase 1b MAD study data in PKD confirm the safety and efficacy needed to advance registrational trials?
- How will the orphan drug status for RP11 influence regulatory timelines and commercial prospects in Europe?
- What impact will preclinical findings in PMS have on the timing and design of first-in-human studies?